Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in non-ambulatory subjects with Duchenne muscular dystrophy
2023-000321-80Phase 2
- Sponsor
- FibroGen
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of pamrevlumab in Duchenne muscular dystrophy (DMD), sponsored by FibroGen. Primary endpoint: Annual change from baseline in percent predicted forced vital capacity at Week 104.
02
Drugs
pamrevlumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2023-000321-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000321-80.